A comparison of patient treatment pathways among multidrug-resistant and drug-sensitive TB cases in Delhi, India: A cross-sectional study

Indian J Tuberc. 2020 Oct;67(4):502-508. doi: 10.1016/j.ijtb.2020.07.020. Epub 2020 Jul 25.

Abstract

Background: The delay in the diagnosis and treatment initiation of patients with MDR-TB worsens individual prognosis and increases the risk of disease transmission in the community. These delays have been attributed to delay in treatment-seeking by the patient and shifting to multiple healthcare facilities before being tested and diagnosed through India's National Tuberculosis Elimination Program (NTEP).

Objective: to identify treatment pathways in patients with MDR-TB from the time of onset of symptoms and treatment seeking until diagnosis at a PMDT site and subsequent treatment initiation. We also compared these characteristics with those of patients with DS-TB.

Methods: We recruited a total of 168 patients with MDR-TB and DS-TB each, in Delhi. Data were analyzed using IBM SPSS Version 25.

Results: The mean (SD) patient delay for initial treatment-seeking was 20.9 (15.9) days in patients with MDR-TB, and 16.1 (17.1) days in patients with DS-TB (p < 0.001). The median time from visit to the first healthcare facility (HCF) until confirmation of MDR-TB diagnosis was 78.5 days, and until treatment initiation was 102.5 days. Among patients with DS-TB, the time interval from a visit to the first HCF until the initiation of ATT-DOTS was 61.5 days.. Patients diagnosed with DS-TB, whose first source of treatment was a private facility (n = 49), reported a significant delay in the initiation of ATT-DOTS (p < 0.001).

Conclusions: Despite the introduction of universal drug sensitivity testing in individuals having presumptive MDR-TB, a significant delay in the diagnosis and initiation of effective MDR-TB treatment persists as a major public health challenge in India.

Keywords: India; MDR-TB; PMDT; Treatment pathways.

MeSH terms

  • Adult
  • Antitubercular Agents / therapeutic use*
  • Critical Pathways* / organization & administration
  • Critical Pathways* / standards
  • Delayed Diagnosis* / adverse effects
  • Delayed Diagnosis* / prevention & control
  • Disease Transmission, Infectious / prevention & control
  • Female
  • Health Services Needs and Demand
  • Humans
  • India / epidemiology
  • Male
  • Microbial Sensitivity Tests* / methods
  • Microbial Sensitivity Tests* / trends
  • Mycobacterium tuberculosis* / drug effects
  • Mycobacterium tuberculosis* / isolation & purification
  • Patient Acceptance of Health Care
  • Prognosis
  • Time-to-Treatment* / organization & administration
  • Time-to-Treatment* / standards
  • Tuberculosis, Multidrug-Resistant* / diagnosis
  • Tuberculosis, Multidrug-Resistant* / epidemiology
  • Tuberculosis, Multidrug-Resistant* / therapy
  • Tuberculosis, Multidrug-Resistant* / transmission

Substances

  • Antitubercular Agents